The journal focuses on the mechanisms and strategies underlying cancer therapy resistance, emphasizing both immune and chemoresistance while highlighting innovative therapeutic approaches beyond conventional pharmacology. The scope distinguishes itself from classical pharmacological drug resistance coverage by integrating immune evasion, cellular dysfunctions, and translational therapeutic strategies.

• Immune Resistance and Immune Evasion Mechanisms
Studies investigating primary and acquired resistance to immunotherapies, including defects in antigen presentation, immunosuppressive tumor microenvironments, immune cell dysfunction or exhaustion.

• Chemotherapy and Immunotherapy Resistance
Mechanistic and molecular investigations of simultaneous resistance across different treatment modalities, particularly chemo-immunotherapy combinations treatments, including signaling pathways, gene regulation, metabolic reprogramming, and crosstalk between different resistance mechanisms.

• Cellular Dysfunction in Therapy Resistance
Research addressing how impairment in physiological functions of cellular organelles such as mitochondria, endoplasmic reticulum, endosome-lysosome compartments, or cellular structures as nuclear structure, plasma-membrane contribute to metabolic stress, chemoresistance and immunoresistance, intended as immune-evasion/immune-suppression or resistance to immunotherapy.

• Resistance to Cell-Based Strategies and CAR-T Therapies
Studies on adoptive cell therapies, including CAR-T cell design, optimization, and mechanistic understanding of resistance or failure in the tumor microenvironment.

• Cancer Vaccines: Mechanisms and Challenges
Investigations into cancer vaccine development, immune activation mechanisms, and reasons for clinical ineffectiveness, aiming to provide insight into overcoming vaccine resistance.

• Nanomedicine and Targeted Therapeutic Strategies
Development and application of nanotherapeutics, intelligent drug delivery systems, and precision-targeted strategies to overcome multi-modal therapy resistance, with a particular focus to strategies aimed at boosting immunotherapy or chemo-immunotherapy efficacy.

• Translational and Preclinical Research
Research spanning from bench to bedside, including mechanistic studies, preclinical models, clinical sample analysis, drug development, biomarker discovery, and evaluation of therapeutic strategies to overcome resistance.

• Interdisciplinary and Emerging Topics
Novel directions based on interdisciplinary studies, derived from the cross-contamination of cancer cell biology, pharmacology, immunology, nanotechnology, personalized approaches to improve multimodal cancer treatment and overcome resistance.